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Brief Introduction 
The association of altered carbohydrate metabolism with 
renal failure has been described and investigated extensively 
since Neubauer first described it in 1910 (17,64,82). Never¬ 
theless, the mechanisms underlying the glucose intolerance 
of uremia remain poorly defined. Elucidation of this mechanism 
might help to provide insight into the mechanism of insulin 
action in general as well as further define the factors con¬ 
tributing to other insulin resistant states such as obesity 
and diabetes mellitus (18,39,67). 
The complexity of glucoregulatcry mechanisms in man 
provides numerous sites at which inhibition or interference 
might result in the glucose intolerance commonly associated 
with uremia (24). Studies suggesting the possibility of a 
defect in insulin synthesis have not proven valid (17). 
However, an abnormality in the early phase of insulin secret ion- 
in uremia has been described (8,12,15,16,17). The role of 
other hormones that affect glucose metabolism has also been 
investigated. These evaluations of the role of glucagon (10, 
15,44,45), growth hormone (24,48,57,84), parathyroid hormone 
(3,42,54), epinephrine (15), corticosteroids (15,17,64), and 
gut hormones (cholecvstekinin, gastrin, secretin)(3) in the 
glucose intolerance of uremia have been extensive and on 
occasion, contradictory. 
Because it is a central organ in the glucoregulatcry 
pathways of the body, the role of the liver has been studied 
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from a number of different perspectives. Alterations in a) 
hepatic glucose uptake, b) hepatic glucose production, c) 
glycogenolysis, have all been extensively studied (9,15,16, 
19,29,34,46,49,59,61,71,73). 
Adding to this complexity are a number of metabolic toxins 
such as urea,creatinine, guanidosuccinic acid, methylguanidine, 
indoles, phenols, and aliphatic amines which accumulate in 
the uremic state and have been described to affect carbohydrate 
metabolism (5,8,9,14,17,30,49,64). Electrolyte abnormalities 
and inhibition of several different enzymes have also been 
implicated in this area (8,17,46,49,55,56,77,78). Many of these 
early studies were flawed by the need to perform in-vitro 
studies of complex in-vivo processes and by the inability of 
investigators to completely eliminate the complex neuro¬ 
endocrine response to experimental manipulation, hypoglycemia, 
etc. 
By using the recently developed insulin clamp technique, 
the present study eliminates many of these problems. With 
this technique, a steady state plateau of hyperinsulinemia 
is created while the plasma glucose level is held constant 
at euglycemic levels by varying the rate of a separate glucose 
infusion. This avoids the neuro-endocrine response described 
above. Since the plasma glucose concentration is held constant 
at the basal level, the rate of glucose infusion must equal 
the rate of glucose uptake by all the tissues of the body and 
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provides a measure of tissue sensitivity to insulin. 
In the present study, we have employed the euglycemic in¬ 
sulin clamp technique to examine tissue sensitivity to insulin 
in the unariesthetized uremic rats and normal controls so that 
some determination of the validity of this model in investigation 
of glucose intolerance in chronic uremia might be made. 
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Introduction 
An understanding of the carbohydrate intolerance of 
chronic uremia requires familiarity with the factors that 
control glucose homeostasis and the points at which these 
mechanisms can be altered in the normal individual. This 
understanding becomes even more difficult in the uremic 
patient, in whom there are accumulations of metabolites 
not present in healthy subjects, and because of the marked 
derangements in hormone and electrolyte concentrations which 
also accompany uremia 
I. Normal Carbohydrate Metabolism 
Following the administration of an oral or intravenous 
glucose load, the plasma glucose concentration increases and 
the resultant hyperglycemia provides a stimulus to pancreatic 
beta cells to release insulin into the circulation. The 
released insulin facilitates the transport of glucose across 
the cell membrane, which in turn leads to a decrease in plasma 
glucose concentrations toward baseline levels. The majority 
of glucose absorbed after oral intake is retained in the 
splanchnic bed, with only 10-15% becoming available to peripheral 
tissues in the resting state (32). Under these conditions, 
then, splanchnic uptake remains the major determinant of the 
shape of the glucose tolerance curve (32). 
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While insulin is known primarily for its role in facil¬ 
itating glucose transport into cells, this hormone is also 
Involved in membrane transport of amino acids, anions, cations, 
and other hexoses (13). Muscle and fat are the tissues most 
dependent on the effects of insulin for transmembrane hexose 
transport. This occurs by a process of facilitated diffusion, 
implying that the concentration gradient across the membrane 
remains an important factor even in the presence of insulin (13). 
Once the glucose is in the cell, it is phosphorylated and 
can no longer diffuse across the cell membrane. The glucose- 
6-phosphate may then be converted to uridine diphosphate glucose 
and be stored as glycogen or utilized in the synthesis of 
mucopolysaccharides. G-6-P might also be oxidized in the 
hexose monophosphate shunt to yield ribose sugars for R3SA syn¬ 
thesis. More commonly, however, the G-6-P will be utilized 
in the Embden-Meyerhof glycolytic pathway. 
In adipocytes, glucose transport into the cell is the rate 
limiting step of glucose metabolism. Once the glucose is in 
the ceil, however, phosphorylation becomes the rate limiting 
step (11). Factors which inhibit other steps in this metabolic 
pathway to rates lower than either of these two steps will 
decrease the rate of carbohydrate metabolism. 
II. Carbohydrate Metabolism in Uremia 
There is general agreement that glucose metabolism is im¬ 
paired in the majority of uremic patients. Such patients 
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demonstrate glucose Intolerance not unlike that of adult onset 
diabetes mellitus. It becomes important to differentiate the 
glucose intolerance of uremia from that of diabetes mellitus 
primarily because diabetics have a significantly greater inci¬ 
dence of serious complications and mortality with hemodialysis 
or transplantation than non-diabetics (17). 
The majority of uremic patients have fasting glucose 
levels in the normal to high range despite elevated fasting 
plasma insulin levels. This suggests the presence of insulin 
resistance. Following both oral and intravenous glucose loads, 
glucose tolerance has been shown to be abnormal (8,15,64). 
Approximately 50% of uremics manifest these signs (17,78). 
These include a delayed, diminished fall in plasma glucose 
after exogenous insulin administration in uremic patients (1664), 
Uremics similarly manifest a delayed decrease in blood glucose 
after administration of oral hypoglycemic agents in the ab¬ 
sence of either drug persistence or beta cell refractoriness (10) 
The degree of insulin resistance demonstrated in abnormal 
glucose tolerance testing has not been shown to correlate with 
the severity of the azotemia (8,64). However, there is a positiv 
correlation between fasting blood sugar levels and blood urea 
nitrogen in uremic patients (78). 
III. Factors which might affect carbohydrate metabolism in uremia 
A- Insulin secretion 
Investigation of the insulin secretory response of uremics 
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to a glucose load have been conflicting (17). Several In¬ 
vestigators have reported a decreased plasma insulin response 
to both oral and intravenous glucose in uremics (44,45). 
However, an equal number of reports have demonstrated either 
a normal (4tt,72),or increased (49,56) plasma insulin response. 
These reports refer only to the early phase of insulin release 
which normally occurs from two to five minutes after elevation 
of plasma glucose levels and is felt to represent the release 
of packets of pre-formed insulin (25), The later, more gradual 
release that occurs throughout the period of hyperglycemia 
has been uniformly reported as increased in uremics after both 
oral and intravenous glucose loading (7,8,45,78). This later 
release is felt to represent the release of newly synthesized 
insulin. 
DeFronzo (15) studied glucose intolerance in uremic patients 
using the glucose clamp technique. He explains that the 
differences between these above-mentioned reports are consistent 
with a spectrum of abnormalities ranging from patients with 
normal beta cell response to glucose to those with markedly 
inhibited insulin secretion. The former group would manifest 
normal fasting plasma insulin levels with an increased early 
and late response to glucose while the latter group would 
have low fasting plasma insulin levels and inadequate or dimi¬ 
nished insulin secretion in response to glucose (15). In 
addition, tangential evidence that some uremics may have 

Inhibition of insulin secretion is provided by the finding that 
the response to intravenous tolbutamide is delayed and di¬ 
minished in uremics (8,44,78), but that this inhibition is 
corrected by dialysis (44,56,78). Although insulin response 
may be inhibited in some uremics, this would not explain the 
elevated fasting insulin levels with normal plasma glucose 
levels found in almost all uremic patients. 
B. Insulin metabolism 
It has been demonstrated that chronic dialysis patients 
have a decreased rate of insulin degradation and an expanded 
body pool of insulin (33). This increased insulin pool is 
greater than that which would be produced by fluid retention 
due to renal failure (33). Another study attributes the hyper- 
insulinemia to a prolonged half life for insulin due to a 
decreased metabolic clearance rate and a prolongation of 
stimulation for pancreatic secretion secondary to the delayed, 
diminished decrease in plasma glucose seen in uremia (48). 
Perhaps the most definitive studies of beta cell response 
are those using the glucose clamp technique. With this tech¬ 
nique, the plasma glucose concentration is acutely raised by 
125 mg. per 100 ml. and maintained at that level by a variable 
glucose infusion. Since all subjects have had their glucose 
levels raised by the same amount, the plasma Insulin response 
provides a measure of beta cell response to hyperglycemia. 
Results of these studies have indicated that the early plasma 

insulin response to hyperglycemia is similar in control 
subjects and uremics. The late response in urernics is 
almost uniformly increased secondary to increased secretion 
and decreased clearance. After dialysis, the plasma insulin 
response decreased by 32% due to an increase in the metabolic 
clearance rate of insulin and a reduction in insulin secretion. 
(15,16,17). Other studies have resulted in similar observations 
(7,8,12,48,50,78). 
C. Alterations in hormone concentrations 
In addition to insulin, the metabolism of several other 
hormones known to be important in glucose homeostasis have 
been reported as abnormal in patients with chronic renal 
failure. Plasma levels of glucagon have uniformly been reported 
to be increased (3,15,73). This is due at least in part to 
a marked decrease in the degradation of glucagon by the uremic 
kidney (73). Since glucagon is known to stimulate hepatic 
glucose production, it is possible that the fasting hyper¬ 
glycemia observed in uremic patients as well as the excessive 
hyperglycemia following glucose administration is secondary 
to elevated basal hepatic glucose production and a failure of 
the liver to normally suppress gluconeogenesis and glycogen- 
olysis following intravenous or oral glucose. Results of 
investigations in this area range from the reports by Cohen and 
Horowitz that patients with significant renal disease failed 

to demonstrate an appropriate increase in plasma glucose in re~ 
sponse to glucagon (10), to Hampers' report of normal response 
to glucagon in the uremic patients he tested (44,45). Others 
report either mild (8) or severe (15,73) hypersensitivity 
to the plasma glucose elevating effects of glucagon in uremics. 
There is somewhat more agreement on the question of glucagon 
levels in uremia. Nearly all authors reported normal levels 
of glucagon secretion despite elevated fasting levels which 
remained elevated throughout glucose tolerance testing (3,15,73). 
These elevations are attributed to a marked decrease in the 
metabolic clearance rate of glucagon in uremics relative to 
controls (73). Despite these observations, it is unlikely 
that this is the major cause of glucose intolerance in uremia. 
The major site of glucagon action is in the liver, where it 
stimulates both glycogenolysis and gluceneogenesis. It has been 
well documented that uremic patients demonstrate no increase 
in basal hepatic glucose production, and that such production 
is normally suppressed by insulin and glucose (15)* In either 
case, dialysis results in decreased glucagon levels,some 
normalization of glucose tolerance, and a normal increase in 
plasma glucose levels in response to glucagon in uremic patients 
(27,73). 
Hyperinsulinemia per se might contribute to some degree 
of glucose intolerance. Insulin is known to regulate its own 
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receptor number so that under conditions of hyperinsulinemia, 
a decrease in the number of insulin receptors takes place (19), 
This decrease might cause a relative resistance to insulin 
effect. 
Elevated growth hormone levels might also contribute 
to carbohydrate intolerance. Elevated fasting growth hormone 
levels have been measured in many uremics (48), However, 
another study found that only 50% of uremic subjects demons cra¬ 
ted this finding, and that only 50% of these demonstrated 
an abnormal growth hormone response to glucose administration (24), 
This latter group manifested a paradoxical rise in growth 
hormone levels after glucose administration (24,48,72), 
Despite the frequent observation of this phenomenon, no cor¬ 
relation has been found between elevated growth hormone levels 
and the degree of carbohydrate intolerance in uremics. No 
change in fasting growth hormone levels is observed after dia¬ 
lysis. No correction of the paradoxical rise in growth hor¬ 
mone levels after glucose administration is seen after dialysis 
despite mrked post dialysis improvements in carbohydrate 
metabolism (24,48,72), It is therefore unlikely that alter¬ 
ations in growth hormone levels or action can satisfactorily 
explain the glucose intolerance of uremia. 
Two other hormones which have been specifically inves¬ 
tigated for their role in glucose intolerance are parathyroid 
hormone arid corticosteroids. In vitro studies of renal 
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tubules from starved rats show that elevated parathyroid 
hormone levels increased gluconecgenesis from lactate, pyru¬ 
vate and glutamate (42). Bagdade observes that parathyroid 
hormone may have a proteolytic effect on muscle, therby in¬ 
creasing the concentration of alanine, a gluconeogenic sub¬ 
strate (3). Despite these observations, there has been no 
correlation observed between elevated PTH levels and uremic 
glucose intolerance, suggesting that PTH is not the cause (54). 
Plassaa corticosteroid levels in uremics have been re¬ 
ported as normal (15) or slightly elevated (17)in uremics. 
Although elevated glucocorticoid levels could promote gluco- 
neogenesis from pyruvate and glycerol, and steroids are 
known to cause cellular insulin resistance (3), there are. no 
reports in the literature of corticosteroid elevations in 
uremia of sufficient magnitude to account for the observed 
effects, and no correlation between the degree of glucose 
intolerance and elevation of steroid levels (17). 
D. Accumulation of toxic metabolites 
A broad range of metabolic products which are normally 
cleared by the kidneys but which accumulate in renal failure 
have also been investigated as causes of glucose intolerance. 
The possibility that some of these might be important in this 
regard is suggested by the observed improvement in carbo¬ 
hydrate tolerance after dialysis (14,15,44,45). Some of the 
substances which have been looked at include urea, creati¬ 
nine, guanidosuccinic acid, methylguanidine (15), indoles, 
phenols, and aliphatic amines (3,10), Further evidence 
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for the role of a dialyzable metabolic product contributing 
to uremic glucose intolerance is the finding that a selective 
low protein diet can correct the intravenous glucose tolerance 
test in uremics who had previously demonstrated glucose 
intolerance (75). 
The first two such metabolites studied were urea and 
creatinine, probably because of their premier position as met¬ 
abolites commonly used to assess renal function. Several 
studies have reported some degree of correlation between 
the severity of carbohydrate intolerance and the degree of 
elevation of urea and creatinine concentrations (44,49,78;. 
In vitro studies examining the effect of urea on glucose 
metabolism have produced conflicting results. In one study, 
incubation of rat hemidiaphragms with plasma from uremic 
rats failed to alter glucose metabolism (13). Another similar 
study revealed that: rat diaphragm incubated with uremic 
serum utilized less glucose than rat diaphragm incubated in 
serum from normal subjects, thereby demonstrating insulin 
resistance (30). In vivo studies have also been conflicting. 
A single patient with normal glucose tolerance developed 
carbohydrate intolerance after urea was added to his dialysate 
(49). This is in contrast to Hampers' report of correction of 
glucose intolerance in uremic subjects dialyzed against 
a. urea bath (44). Abnormal glucose tolerance was shown to 
develop in three male volunteers after three days of ingest¬ 
ing sixty grams per day of urea (64). The conflicting 
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reports about the direct effects of creatinine and urea on 
carbohydrate metabolism suggest that these are not principally 
responsible for he observed glucose intolerance (5), While 
the concentrations of these two metabolites are the mere 
commonly used indicators of renal disease, other metabolites 
increase in concentration to parallel the degree of renal 
failure as well. It may be one of these other metabolites 
not commonly measured which accounts for the correlation 
between urea and creatinine levels and glucose intolerance (44, 
78). Exactly which of the multitude of toxic metabolites 
this might be is unclear. Guanidosuccinie acid has been 
considered on the basis of its theoretical ability to inhibit 
phosphorylation of ADP to ATP (10). However, no such inhi¬ 
bition has been demonstrated in rats either in vivo or in 
vitro (9). In summary, there is little direct evidence to 
support the concept that any of the above mentioned metabolites 
is solely responsible for the carbohydrate intolerance of 
uremia. 
E. Alterations in electrolyte concentrations 
Alterations in electrolyte concentrations are common 
in uremic patients and could conceivably contribute to the 
impairment of carbohydrate metabolism. 
Potassium levels are normally increased in chronic renal 
failure. After dialysis they are either unchanged from pre¬ 
dialysis levels (45) or slightly decreased (17). In addition, 

15 
most authors report improved glucose tolerance after dialysis. 
Only markedly decreased potassium levels have been shown 
to have detrimental effects on glucose tolerance (38), most 
probably because potassium has a direct stimulatory effect 
on pancreatic insulin secretion in vitro (41), While one 
study reported improved glucose tolerance after potassium 
replacement on patients with low levels of total exchangeable 
body potassium (59), another similar study found no such im¬ 
provement (49), The fact that most: uremic patients are hyper¬ 
kalemia and the lack of correlation between either serum 
potassium levels or total exchangeable potassium levels makes 
it highly improbable that alterations in potassium levels 
plays a significant: role in the carbohydrate intolerance of 
uremia (8,17,49,77,78). 
Calcium is another ion with the potential for altering 
glucose metabolism when its concentration varies from the 
normal range, which does occur in uremia. An elevated serum 
calcium level allows normal pancreatic insulin secretion but 
results in decreased peripheral sensitivity to the released 
hormone (2)c Low serum calcium levels cause a marked reduction 
in pancreatic insulin secretion without altering tissue 
sensitivity to insulin, 
result in a decrease in 
glucose tolerance test, 
may be even more sens it 
Either of these situations might. 
glucose utilization and an abnormal 
Evidence suggests that uremic patients 
ive than normals to these effects. While 
:a .cium infusion in hypocalcemia uremic patients normalized 
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their glucose tolerance tests, equally hypocalceraic control 
subjects had no evidence of glucose intolerance at all (55), 
The calcium infusion did not measurably increase basal plasma 
insulin concentration in the uremics, however, so the mech¬ 
anism which might account for the improvement remains uncertain 
(55). 
There is no evidence to support the idea that other ions 
might cause uremic glucose intolerance. Patients with chronic 
renal failure usuallly have elevated phosphate levels. Only 
markedly decreased phosphate levels have been shown to result 
in decreased glucose tolerance. While diet-induced hypo¬ 
phosphatemia decreased glucose clearance by 30% in dogs, their 
response to exogenous insulin was then more marked than that 
of controls (46). This is in marked contrast to the insulin 
resistance which accompanies uremic carbohydrate intolerance. 
Alterations in magnesium levels have similarly not been found 
to correlate with glucose intolerance, and no change in serum 
magnesium levels is found after dialysis despite improved 
glucose tolerance (45,72), 
While acidosis has been found to result in abnormal 
responses to intravenous glucose and to exogenous insulin, 
the degree of acidosis commonly found in renal failure is of 
itself not sufficient to produce the observed effects (18). 
F. Decreased Insulin clearance 
Certain changes which accompany renal failure may of 
themselves contribute to the observed hyperinsulinemia. As 

discussed above, hyperinsulinemia causes a decrease in the 
number of insulin receptors and thereby creates a relative 
insulin resistance. The normal kidney cells of the p?cox- 
imal tubule actively remove insulin from tne tubular lumen 
and from the peritubular cells. Only resorption from the 
lumen depends in oxidative metabolism. When the glomerular 
filtration rate falls in renal failure, the net rate of 
insulin removal from the renal plasma decreases despite a 
compensatory increase in peritubular absorption (65). The 
renal tubular cells then degrade the insulin, thereby re¬ 
ducing circulating insulin levels (27). Thus, the half life 
of insulin in uremic or anephric patients is markedly pro¬ 
longed. The contribution of this increased half life to¬ 
ward uremic hyperinsulinemia can be calculated by measuring 
the difference in insulin concentration between the renal 
artery and vein in both-normals and uremics. When this was 
done (70), a 30-40% decrease in insulin concentration was 
measured across the kidney. Accounting for plasma flow, 
10-15% of the daily basal insulin output is shown to be de¬ 
graded by the kidney. This can be reduced to as little as 
2% of normal in severe renal failure (70). Decreased renal 
clearance of insulin alone does not explain the improved 
glucose tolerance and increased metabolic clearance rate of 
insulin after dialysis. Suppression of insulin degradation 
at another site such as the liver by a dialyzable toxin must 
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also be considered. 
There is also evidence to suggest that other peptides 
are handled in the same way as insulin in renal disease. 
This might account for increases in levels of circulating 
ACTH, growth hormone, and glucagon (70). The fractional ex¬ 
traction of glucagon across intact rat and dog kidneys, for 
example, is normally 40%. This reduces to near zero in 
severe renal failure (73). This results in decreased clear¬ 
ance and a resultant prolonged half-life for these peptides. 
It is, in fact, this mechanism which is considered respon¬ 
sible for the decreased insulin requirements of diabetic 
patients who subsequently develop renal failure. 
IV. Mechanisms of Observed Carbohydrate Intolerance 
Having described the possible roles of all those factors 
which might contribute to abnormal glucose tolerance in 
uremia, it remains to discuss the sites of these effects. 
Two distinct possibilities emerge if ve assume that, as the 
studies show, insulin secretion in uremics is adequate. Either 1) 
there is a problem with hepatic glycogen storage and release 
and/or a failure of the liver to suppress he jjvx* Qt O ih €? gl U cose pro¬ 
duction normally in response to insulin, or 2) there is pe¬ 
ripheral resistance to the effects of insulin. 
A. 1, Hepatic glycogen 
If the liver were not taking up an appropriate amount of 

glucose from an oral or intravenous lead, ore might expect 
that hepatic glycogen stores would be decreased. Several 
studies nave demonstrated that such is not the case. First, 
as noted above, the plasma glucose response to glucagon is 
either normal or increased in uremia. Since the major source 
of this glucose is hepatic glycogenolysis, glycogen stores 
must be adequate. Secondly, direct measurement of glycogen 
in the livers of chronically uremic rats have found no 
differences between uremics and controls (6,29), Another 
mechanism for raising plasma glucose levels is gluconeogenesis. 
Studies by Rubenfeld and Garber suggest that basal hepatic 
glucose production in uremia is significantly elevated. One 
attempt to quantify this difference placed it at 38% above 
control levels(69). This study has been questioned because 
of their use of a glucose labelled in the #2 position, which 
has been found to overestimate glucose turnover in other 
studies due to "futile cycles" (!). Nevertheless, another 
study using different tracers has reported an increased level 
of gluconeogenesis in the uremic liver (69), Theories 
about the cause of this increase include the idea that the 
increased protein catabolism found in uremia protides elevated 
levels of amino acids which are gluconeogenic substrates (34). 
Normal inhibition of protein catabolism by insulin is felt 
not to occur (36). Certainly, the enzymes required for glu¬ 
coneogenes is are present at higher levels than those of control 
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SOFT and SCOT levels are elevated In the livers of uremic 
rats (34). Phosphoenol pyruvate carboxykinase activity increases 
more rapidly in response to fasting in uremic rats than in 
controls (4), and this is accompanied by a greater increase 
in serum alanine, free fatty acids and glycerol in ureniics 
than in controls. All of these* changes suggest greater 
propensity toward gluconeogenesis in uremic subjects (4). 
A.2. Suppression of hepatic glucose production. 
Despite this biochemical predisposition toward gluco~ 
neogenesis in the basal or fasting state, there is nearly 
uniform agreement that hepatic glucose production is normally 
suppressed by physiologic levels of insulin (15,16,25,60). 
In humans, insulin secretion was found to decrease hepatic 
glucose production from basal levels by approximately 87% 
in both uremic and control subjects tested by insulin clamp 
(15,16,19), Another study reports similar suppression and 
notes no difference in the suppressive effects of insulin 
on hepatic glucose produaction either before or after dialysis 
(25). Similar studies in chronically uremic rats showed 
an unquantified but steady decline in hepatic glucose pro¬ 
duction after insulin administration (71) 9 while another 
study in acutely uremic rats showed no difference In suppression 
of hepatic glucose production between uremics and controls (60). 
It is clear from these studies that despite the presence 

21 
of increased gluconeogenic capability in uremia, hepatic- 
glucose production is normally suppressed by insulin. This 
makes it improbable that elevated hepatic glucose production 
plays a major role in uremic carbohydrate intolerance. 
B. Insulin resistance 
Finally, there is the possibility that peripheral 
resistance to the effects of insulin is a major factor in 
the uremics’ altered carbohydrate metabolism. Several sources 
suggest, that this is the case. The observation of a decreased 
response of muscle and fat to insulin in uremia is a nearly 
constant one. Using the isolated, perfused hindlimb pre¬ 
paration, Mondon, Dolkas, and Heaven (60) have shown that the 
ability of insulin to increase glucose uptake in uremic rat 
tissues was markedly decreased compered to controls. Fore¬ 
arm perfusion studies in humans by Westervelt (82,83) revealed 
that perfusion with insulin resulted in an increase in glucose 
uptake in uremics only 25% as great as in controls. This same 
study showed that there was & marked decrease in phosphate 
uptake in uremics, but that lactate production per unit of 
glucose taken up was equal in both groups. This implies an 
intact Embden-Meyerhof pathway but inhibition of either glu¬ 
cose transport into the cell or intracellular phosphorylation. 
The other phenomena observed in uremics, namely elevated 
fasting insulin levels with normal or slightly elevated fast- 

ing blood sugar and delayed, diminished response to exogenous 
insulin are both most consistent with peripheral insulin 
resistance (17). Little is known about how this occurs, 
other than the decreased phosphate uptake mentioned above. 
There are numerous sites in the glucose metabolic pathways 
at which phosphorylation is a key step essential to normal 
utilization. Rat diaphragm incubated in uremic serum had 
a higher ratio of free glucose within the cell relative to 
concentrations in the medium than diaphragm incubated in 
normal serum(30). This suggests inhibition of glucose phos¬ 
phorylation intracellularly. The same study revealed that 
despite utilizing less glucose than rat diaphragm incubated 
in normal serum, concentrations of glucose-6-phosphate and 
fructose-6-phosphate increased vjhile the concentration of 
fructose-1,6"diphosphate fell. This suggests that the in¬ 
hibited enzyme is phosphofructokinase (30). Luke, et al, 
in another study (58), reported that despite abnormal glucose 
tolerance tests, uremic patients had fructose tolerance tests 
nearly identical to those of controls. Since fructose 
metabolism occurs primarily in the liver and its transport 
is not insulin dependent, the authors concluded that there 
was no generalized abnormality of carboydrate metabolism in 
the liver, and that the E mb den-Meyerhof glycolytic pathway 
functioned normally below the level of fructose-1,6-diphosphat ^ C 
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The fact that these studies are in such close agreement despite 
being conducted by different investigators in different 
tissues (muscle (30) and liver (58)) strongly suggests that 
inhibition of phosphofructokinase by uremic serum is a major 
contributor to the abnormal glucose metabolism observed in 
uremia. 
Despite these extensive investigations and resultant 
evidence for the roles of numerous metabolic alterations 
which accompany renal failure and might cause insulin re¬ 
sistance, no single mechanism has been proven to account 
for the full extent of the alteration in glucose metabolism. 
It is highly probable that the total phenomenon is a summation 
of a spectrum of lesser alterations which exist in different 
combinations and degrees in individual patients. 

Methods 
Male Sprague-Dawley rats were received and housed in a 
constant temperature room with a twelve hour day-night cycle. 
Insulin clamp studies were performed on animals which had 
been fasted overnight but allowed free access to water. 
Experimental (uremic group) animals were received one 
month prior to study as weanling males. They were housed 
under the conditions described above for five days prior to 
any manipulation. On the fifth day, a remnant nephrectomy 
procedure was performed on the right kidney. Animals were 
anesthetized with intra-peritoneal Nembutal (0.08 mg. per 
100 grams body weight), then shaved over the right flank. 
A small, vertical skin incision was made and carried through 
the muscle layers to expose the righc kidney. This v/as 
gently lifted from position and placed in a specially made 
retractor just outside the incision with all structures in¬ 
tact. The renal capsule was then incised near the renal 
pelvis to expose the structures at the uretero-vascular pole. 
Under a dissecting microscope, all branches of the renal 
artery were identified. Leaving only the single, most cephalad 
branch intact to perf use the upper pole, all other branches 
were ligated with 4-0 silk suture material. Visual inspection 
of the kidney revealed that only 10-15% of the renal tissue 
remained perfused after this procedure. The kidney was then 
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gently re-inserted into its original retroperitoneal po¬ 
sition and the wound closed in a single layer with stainless 
steel clips. The animals recovered quickly, were housed in 
individual cages and fed a prepared commercial rat diet from 
that point until the night before the clamp study. 
One week after the 85% right nephrectomy procedure, 
the left kidney was entirely remonved through a flank incision 
as described above. The uremic group consisted of ten 
animals. 
Ten rats served as a control group. These were treated 
in an identical fashion to the uremic rats except that the 
nephrectomy was not performed. 
Two weeks after the second nephrectomy procedure and 
four days prior to study, chronic indwelling catheters 
(PE-50 polyethylene tubing) were placed into the jugular 
vein and carotid artery of both the uremic and control rats. 
The venous catheter provided access for infusion into the 
rat while the carotid catheter was for the non-traumatic 
removal of blood for glucose and insulin determinations. 
Catheter placement 
For the catheter placement, animals were once again 
anesthetized using intr-peritoneal injection of Nembutal 
at 0.08 mg. per 100 grams body weight, then shaved at the neck 
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and at the nape of the neck. A vertical midline incision 
was made in the skin from a point midway between the man¬ 
dibular angles to the sternal notch. The skin was reflected 
on the right side and blunt dissection carried down to ex¬ 
pose the jugular vein. The vein was then ligated approxi¬ 
mately 5 min. above its convergence with the cephalic vein 
and a small nick made in the vessel just below the ligature. 
A PE-50 polyethylene tube with a prepared tapered tip was 
inserted through the nick and threaded through the superior 
vena cava into the right atrium. The catheter was tied in 
place and 0.2 cc. of a solution of saline and 100 units per 
ml. of heparin v?as flushed through the tubing to prevent 
clotting within the catheter lumen. The external end of the 
tubing was then plugged. 
The right carotid artery was then exposed by incising the 
aponeurosis and reflecting the sternocleidomastoid and the 
strap muscles. The artery was then carefully dissected off 
the accompanying vagus nerve and elevated. A ligature of 
4-0 silk vias then placed on the artery as far cephalad as 
possible. A small serrafine clamp was then placed across the 
vessel as proximally as was practicable in each animal, A 
small nick was made in the artery proximal to the ligature 
and a catheter identical to the one placed in the jugular vein 
was inserted and held securely in place while the serrafine 
clamp was removed. The catheter was then advanced carefully 
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through the brachiocephalic artery into the aorta. This 
arterial catheter was then flushed with heparinized saline 
and capped after being secured with 4-G silk ties. 
Both arterial and venous catheters were then routed 
subcutaneously to exit via a skin incision at the back of the 
animals head. All animals recovered rapidly from this pro¬ 
cedure, moving, eating, and drinking within three hours. 
All catheters were flushed daily with 0.2 cc. of the heparin¬ 
ized saline solution to maintain patency. 
All of the nephrectomized animals developed clinical 
signs of the uremic syndrome within four days. These included 
pallor of the eyes, ears, and tail, dryness and coarseness 
of hair, and irritability with occasional fine twitches (4). 
Their rate of weight gain was also decreased. 
Four days after catheter placement, euglycemic hyperinsulin 
clamp studies were performed to quantify<tissue sensitivity 
to insulin in both groups. 
Euglycemic insulin clamp 
Animals were fasted from 6 P.M. of the night before 
study until after completion. During the study, animals 
were placed in a small plexiglass cage which allowed them 
enough room to rest comfortably but not move excessively. 
Cages were clear, well ventilated, and allowed access to 
the jugular and venous catheters through a slot in the top 
of the cage. 
e 
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An insulin infusion was prepared at a concentration of 
40 thousand micro-units per ml. using crystalline porcine 
insulin (U-4Q, Lilly Co., Indianappoli.s, Indiana). This 
infusate was made up in normal saline containing 300 mg. 
serum albumin per 100 ml. to minimize adherence of insulin to 
glassware or plastic tubing. All lines were flushed with 
an insulin free saline-albumin solution prior to their use 
in the insulin clamp study. Over the first eight minutes 
of the study an empirically determined priming dose of 
insulin designed to raise the plasma insulin concentration 
by approxiamtely 100 micro-units per ml. was administered. 
This was followed by continous infusion of insulin at a rate 
of 4.4 micro-units per gram of body weight per minute for a 
total of 120 minutes. The insulin perfusion was administered 
via Harvard perfusion pump. 
During the two hour period of insulin infusion,the plasma 
glucose concentration was maintained in the euglycemic range 
with a variable infusion of 5% dextrose in water. During the 
first four minutes of the study, no glucose was infused. 
From four to ten minutes, glucose infusion was begun at 10 
micrograms per gram of body weight per minute. From 10 minutes 
until the end of the study, the arterial plasma glucose 
concentration was determined at 5 to 10 minute intervals. 
Alterations were made in the glucose infusion rate to maintain 
the plasma glucose concentration constant at the desired level. 
Insulin levels were drawn at 30 minute intervals. 
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T&Dle 1 
The Prime-Continuous Insulin Infusion 
Employed During the Euglycemic Insulin Clamp. 
Time (min.) Insulin infusion rate 
micro U./gram/min« 
0-2 8.4 
2-8 6.0 
8-120 4.4 
3 
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Computations-Glucose metabolism 
During the first twenty minutes of insulin/glucose 
infusion, the plasma glucose concentration dropped by 15- 
20 mg. per deciliter. Thereafter, it was maintained within 
a narrow range of the twenty minute value. Under these 
steady state conditions of euglycemia, the rate of glucose 
infusion must be equal to the amount of glucose taken up 
and metabolized by all the tissues of the body. Therefore, 
the glucose infusion rate provides a measure of insulin- 
stimulated glucose metabolism. This assumes that there is no 
source of endogenous glucose production during the study, 
i.e. that hepatic glucose production is completely suppressed. 
To the extent that this is incorrect, the total rate of 
glucose metabolism will be underestimated. Although this 
study does not quantitate hepatic glucose producticn,previous 
studies in man and in rats have shown that hepatic glucose 
production is decreased by 90-95% when the plasma insulin 
concentration is raised by 100 micro-units per ml. More 
importantly, there is no significant difference in this sup¬ 
pressive effect between normal and uremic subjects (15,16,19,25, 
60,71). Preliminary studies to develop an adequate method 
for determining hepatic glucose production in rats using 
a radioactive tracer technique have been performed. However, 
until this technique is further perfected, rates of glucose 
metabolism measured as glucose infusion rates may underestimate 
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the actual rate of glucose metabolism. 
Studies by DeFronzo and Ferrannini (21) have shown that 
elevation of the plasma glucose concentration will increase 
the rate of glucose metabolism in direct proportion to the 
increase in the plasma glucose level. Since the steady state 
plasma glucose concentration during the clamp differed slightly 
between the uremic and control groups, the results are also 
expressed in terms of glucose clearance, (mean rate of glucose 
metabolism/steady state plasma glucose concentration). 
The mean of the plasma insulin concentrations at; 30, 
60,90, and 120 minutes was used to determine the steady state 
plasma insulin level. 
Analytic method s 
Plasma glucose determinations were performed on 50 micro 
liter aliquots of plasma by the glucose oxidase method (Yellow 
Springs Instruments, Model 23A glucose analyzer, Yellow Springs 
Ohio). Plasma insulin determinations were performed by a 
rs dio11nmun©assay technique. 
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Results 
Fasting plasma insulin levels prior to the initiation 
of insulin infusion were 31 + 3 j^U/ml in the uremic rats, 
but only 21 + 4 j^U/ml in the control animals (p'COS ). 
Steady state plasma insulin expressed as the average of half 
hourly measurements begun 30 minutes after the prime-continuous 
insulin infusion was begun (Table 1) were 141 + 8 jijU/ml in 
the uremic group, but 149 + 16 tUJ/ml in controls 9 (table 2) 
After a 16-18 hour fast, baseline plasma glucose concentra¬ 
tions were higher in urernics (146 t 5. mg/dl) than in the 
controls (120 + 5 cag/dl) (p*4 0Gl ). Steady stare plasma 
glucose concentrations were 120 + 4 mg/dl in the uremic 
rats and 104. + 2 mg/dl in control animals (p < ,01 ), 
The mean decrease in plasma glucose over the course of the 
study v?as 25.44 mg/dl in the uremic group and 15,51 mg/dl in 
the control group (p <C ,05 ). (Table 2). 
Glucose metabolism over the course of the 120 minute study 
averaged 12.17 + 0.70 micrograms/gram/minute in urernics and 
16.08 + 0.89 micrograms/gram/minute in controls ( p<4001 ) 
(Tables 3 and 4), The rate of glucose metabolism rose very 
rapidly during the first 30 minutes of glucose and insulin 
infusion, then levelled off to nearly constant values (Tables 
3 and 4) 
Glucose clearance values were calculated to eliminate 
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error introduced by differences in steady state plasma 
glucose concentrations between the two groups (Table 6). 
Studies by DeFronzo and Ferrannini (21) have shown that 
for a given plasma insulin concentration, glucose clearance 
is constant despite changes in plasma glucose concentration 
within the physiologic range. 
Glucose clearance averaged 10.28 -f 0,78 ml/kg»min in the 
uremic rats, but was significantly higher at 15.55 + 1,1 ml/kg#min 
in control rats under similar conditions of hyperinsulinemia. 
(pv4001 ) (Table 6 and Figure 1). In parallel with glucose 
metabolism, glucose clearance increased greatly from the 
first twenty minute time period to the second, then tended 
to level off to a much slower rate of increase for the re¬ 
mainder of the 120 minute study. (Figure 1). 
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Table 2 
Charcteristics of Uremic Animals and Controls 
Uremics 
Body 
Weight 
(grams) 
(1) 
Fasting 
Plasma 
Glucose 
(mg * */d1) 
(2) 
Steady 
State 
Plasma 
Glucose ** 
(3) 
Fasting 
Plasma 
Insulin 
CuU/ml.) 
(4) 
Steady 
State 
Plasma 
Insulin * 
(5) 
(n~l0) 1 55 146 120 31.3 141 
±8 +5 +4 ^3 +8 
Controls 
(n=10) 141 120 104. 21.4 149^ 
+4 + 5 + 2 ±4 +i i 
Values expressed as mean 4; SE. 
* Mean insulin concentration from 30-120 minutes. 
** Mean glucose concentration from 0-120 minutes. 
(1) p less than .05 
(2) p less than .001 
(3) p less than .01 
(4) p less than .05 
(5) p less than .3 (not significant) 
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Table 5 
Mean Glucose Values During 
Euglycemic Clamp 0-120 minutes 
mg./dl. 
Subject 
UREMIC 
mean + SE 
Control 
mean + SE 
1 111 + 4 97 + 6 
2 no + 3 95 + 5 
3 99 + 4 107 ± 5 
4 105 3 100 + 3 
5 128 + 5 112 + 3 
6 123 + 5 104/ + 3 
7 138 + 6 108 + 3 
8 125 + 3 106 + 2 
9 137 + 3 110 ± 2 
10 130 + 4 105 + 3 
Mean 121 104 
SE +4 + 2 
All values expressed as mean + S.E. 
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Table 6 
Mean bate of Glucose Clearance 
from 0-120 minutes 
OREMICS 
mean mean mean 
glucose glucose g1ucose 
ub ject metabolism concentrat ion clearance 
rate (plasma) rate 
(mg/kg/min) (mg/ml) (ml /kg* min 
1 11.13 1.10 10.12 
2 11.71 1.10 10.65 
3 14.80 0.98 15.10 
4 10.54 1.04 10.13 
5 14.00 1.28 10.94 
6 16.58 1 .23 13.48 
7 10.08 1.38 7.30 
8 9.75 1 .25 7.80 
9 11 . 58 1 .37 8.45 
10 11 . 50 1.30 8.85 
Mean 12,17 1.20 10.28 
«k3E 0.70 
. 044 1 
1 
COMROLS 
i i 21.68 0,97 22.35 
2 1 9.77 0.95 20.81 
3 15.91 1 .07 14.87 
4 1 7.02 1.00 1 7.02 
5 1 4.43 1.12 12.88 
6 16.71 1,04 16.0 7 
7 14.80 1.08 13,70 
8 14,46 1.06 13.64 
9 12.60 1.10 11.45 
10 13.38 1.05 12,74 
Mean 16.08 1.04 15,55 
+SE 0,89 .018 1 
p <.001 p <• 01 p <. 001 
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Discussion 
This present study has reviewed the literature pertaining 
to carbohydrate intolerance of uremia and considered the 
mechanisms through which this phenomenon might occur and 
the sites at which these various factors might exert their 
influence to produce the observed effects. In addition, it 
has examined the validity of the uremic rat model for use 
in the study of this phenomenon by use of the euglycemic 
insulin clamp technique. (15,19,23) This technique offers 
many advantages over previous methods of investigation of 
glucose metabolism. It provides a means for study of the 
live, unanesthetized rat. It also allows the study of sensi¬ 
tivity to exogenous insulin over a prolonged time period during 
which equilibrium may be achieved. The complex neuro-endocrine 
response to hypoglycemia which plagued previous such studies 
is avoided, since the subject never becomes hypoglycemic. 
Previous studies such as the insulin tolerance test (8.64) and 
quadruple infusion techniques (68) relied upon pharmacologic 
manipulation to block these responses. Whether this block 
was complete or free of other effects is not known. 
The current study supports the presence of fasting hyper- 
insulinemia which has been reported in previous studies (8,64). 
It is also consistent with reports of elevated fasting blood 
sugar levels reported by several authors in the uremic subjects 

they studied (8,17,64,78). 
Previous reports of a diminished response to insulin 
in uremic subjects relative to controls were supported 
by the results of this study (8,16,19,44,78), Examination 
of the graph of mean glucose clearance rate for each twenty 
minute time period reveals that the lines for each group 
are nearly parallel, but that the glucose clearance rate for 
the uremic group is significantly lower at all points (p<.G0i). 
The mean rate of glucose metabolism for each of the two 
groups demonstartes a similar relationship, however, recent 
studies by DeFronzo and Ferrannini (21) have shown that 
for a given level of plasma insulin the glucose clearance 
rate remains constant despite differences in plasma glucose 
concentrations within the physiological range. Glucose 
clearance rates would therfore seem to be a better indicator 
of glucose metabolism than glucose metabolism rates alone. 
This is undoubtedly due to the fact that insulin stimulated 
glucose transport occur by a mechanism of facilitated 
diffusion (13), As a result, differences in plasma glucose 
concentration effectively alter the concentration gradient 
across the cell membrane of free glucose, This results in 
a steeper gradient and an increase in glucose uptake per 
unit time. The use of glucose clearance rates cancels out 
the effect of such differences. 
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Having demonstrated a diminished response to exogenous 
insulin in uremic rats (i.e.-insulin resistance), it remains 
to discover the site of such resistance. Insulin exerts its 
glucose transport effect in peripheral tissues such as muscle 
and fat. If these tissues were resistant to insulin effect 
then the present observation of decreased glucose utilization 
would be the expected result. However, the possibility also 
exists that the observed phenomena are not the result of 
decreased transport, but of a failure of hepatic glucose pro¬ 
duction to be normally suppressed by hyperinsulinemia (15). 
Some attempts were made to address this question through 
the development of a tritiated glucose tracer technique for 
measuring the rate of appearance (R ) of glucose during the 
euglyeemic insulin clamp. Since the animals were fasted 
prior to study there would be no glucose appearance through 
absorption from the gastrointestinal tract. Any difference 
between the Ra for glucose and the known rate of infusion 
could then be attributed to hepatic glucose production. A 
comparison of basal hepatic glucose production and that measured 
later in the study would indicate the degree of suppression. 
(15,71). Insulin normally suppresses basal hepatic glucose 
production from 80 to 95%, and this suppression has been 
observed to be nearly identical in normal and uremic subjects 
(21,25,60). Problems with the infusate volumes and sample 
volumes required are in the process of being corrected in this 
technique, and should provide valuable information if perfected. 
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In the absence of direct measurements to prove that 
hepatic glucose production is normally suppressed in the 
uremic group, the numerous reports cited above which have 
supported the finding strongly suggest that failure of 
insulin to suppress hepatic glucose production is not the 
mechanism of insulin resistance in uremia. The possibilty 
which then remains is that it is the resistance to insulin 
effect in muscle and fat which result in the observed fas¬ 
ting hyperinsulinemi.a and decreased glucose clearance under 
identical conditions of insulin concentration. The numerous 
metabolic products, ions, electrolytes and other serum com¬ 
ponents whose concentrations and metabolisms are altered in til 
uremic state have been discussed earlier in this work. The 
present study does not examine which of these might cause 
the alterations in glucose metabolism associated with uremia. 
Biochemical analyses (30,58) have pointed to inhibition of 
phosphofructokinase in the Ernbden-Meyerhof glycolytic path¬ 
way as the site at which one or more factors present in uremic 
subjects at levels significantly different enough from control 
to inhibit this enzyme may work to produce insulin resistance. 
In conclusion, study of this chronic uremic rat model 
by the euglycemic insulin clamp technique resulted in the 
findings of fasting hyperinsulinemia, fasting hyperglycemia, 
and a markedly diminished response to exogenous insulin re¬ 
sulting *in diminished glucose clearance. These results support 
the validity of this model for the study of uremic glucose 
intolerance. 
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